Leadership Announcement: Welcoming Our New CEO and CSO
01 April 2025
We are pleased to announce the appointment of Mr. Jason Foo as Chief Executive Officer (CEO) and Dr. Brian Wang as Chief Scientific Officer (CSO) of Pathnova Laboratories Pte Ltd (Pathnova), effective 1 April 2025. Alongside their new roles, Mr. Foo and Dr. Wang will also join Pathnova’s Board of Directors, where they will play a pivotal role in shaping the company’s strategic direction.
This leadership transition comes at an exciting juncture for Pathnova, following our recent merger with Angsana Molecular and Diagnostics Laboratory Pte Ltd. As part of this development, both Pathnova and Angsana are now wholly owned subsidiaries of a newly formed holding company, Archerfish Precision Diagnostics Pte Ltd (Archerfish). As we embrace this new chapter, current CEO Dr. Ian Cheong will step down from both the CEO position and the Pathnova Board. However, he will continue to support the broader enterprise as a Board Member of Archerfish, where he will help guide scientific strategy. He will also remain involved as a scientific adviser to Pathnova. Dr. Cheong has expressed full confidence in Mr. Foo and Dr. Wang and looks forward to witnessing the next phase of Pathnova’s development under their stewardship.
Both Mr. Foo and Dr. Wang bring a wealth of experience and a proven track record at Pathnova. Mr. Foo joined the company in 2018 and eventually became its Chief Operating Officer (COO). His leadership has been instrumental in driving operational excellence and fostering a culture rooted in action and measurable outcomes. Dr. Wang joined in 2021 as Technical Manager and has consistently demonstrated outstanding dedication to advancing our operational and scientific capabilities. His work in assay development has had a lasting impact on our organization. Their joint leadership was most notably demonstrated during Pathnova’s COVID-19 testing operations, where they led the team through unprecedented challenges and were nationally recognized for their contributions. Under their guidance post-pandemic response, Pathnova achieved key milestones, including ISO 13485 and CAP accreditations, as well as HSA approval for our in vitro diagnostic (IVD) kits.
As they step into their new roles, the Board of Pathnova has every confidence that Mr. Foo and Dr. Wang will continue to elevate the company’s mission, values, and capabilities. Their leadership marks a bold new era for Pathnova and we look forward to the journey ahead.